|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EEF1AKMT1 |
Gene summary for EEF1AKMT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EEF1AKMT1 | Gene ID | 221143 |
| Gene name | EEF1A lysine methyltransferase 1 | |
| Gene Alias | ESP13 | |
| Cytomap | 13q12.11 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024RDN3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 221143 | EEF1AKMT1 | HCC1 | Human | Liver | HCC | 3.05e-02 | 2.65e+00 | 0.5336 |
| 221143 | EEF1AKMT1 | HCC2 | Human | Liver | HCC | 7.09e-08 | 3.25e+00 | 0.5341 |
| 221143 | EEF1AKMT1 | S028 | Human | Liver | HCC | 1.19e-10 | 3.25e-01 | 0.2503 |
| 221143 | EEF1AKMT1 | S029 | Human | Liver | HCC | 8.78e-13 | 4.30e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:00434141 | Liver | HCC | macromolecule methylation | 183/7958 | 316/18723 | 2.00e-08 | 4.72e-07 | 183 |
| GO:0032259 | Liver | HCC | methylation | 206/7958 | 364/18723 | 3.35e-08 | 7.53e-07 | 206 |
| GO:00064792 | Liver | HCC | protein methylation | 111/7958 | 181/18723 | 2.36e-07 | 4.18e-06 | 111 |
| GO:00082132 | Liver | HCC | protein alkylation | 111/7958 | 181/18723 | 2.36e-07 | 4.18e-06 | 111 |
| GO:00180221 | Liver | HCC | peptidyl-lysine methylation | 74/7958 | 131/18723 | 8.46e-04 | 5.06e-03 | 74 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EEF1AKMT1 | SNV | Missense_Mutation | novel | c.13G>C | p.Glu5Gln | p.E5Q | Q8WVE0 | protein_coding | tolerated(0.05) | benign(0.095) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| EEF1AKMT1 | SNV | Missense_Mutation | c.38N>G | p.Ser13Cys | p.S13C | Q8WVE0 | protein_coding | deleterious(0.04) | possibly_damaging(0.514) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EEF1AKMT1 | SNV | Missense_Mutation | novel | c.142T>C | p.Trp48Arg | p.W48R | Q8WVE0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EEF1AKMT1 | SNV | Missense_Mutation | c.138N>T | p.Glu46Asp | p.E46D | Q8WVE0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| EEF1AKMT1 | SNV | Missense_Mutation | rs368022750 | c.601C>T | p.Arg201Cys | p.R201C | Q8WVE0 | protein_coding | tolerated(0.24) | benign(0.223) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| EEF1AKMT1 | SNV | Missense_Mutation | c.158N>G | p.Phe53Cys | p.F53C | Q8WVE0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| EEF1AKMT1 | SNV | Missense_Mutation | novel | c.368N>A | p.Pro123Gln | p.P123Q | Q8WVE0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A01N-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | SD |
| EEF1AKMT1 | SNV | Missense_Mutation | rs749657822 | c.484N>T | p.Arg162Trp | p.R162W | Q8WVE0 | protein_coding | deleterious(0) | possibly_damaging(0.511) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EEF1AKMT1 | SNV | Missense_Mutation | rs748024573 | c.293C>T | p.Ser98Leu | p.S98L | Q8WVE0 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| EEF1AKMT1 | SNV | Missense_Mutation | c.412N>A | p.Val138Ile | p.V138I | Q8WVE0 | protein_coding | tolerated(0.14) | possibly_damaging(0.572) | TCGA-AX-A06H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |